



Erratum

To cite this article: (2012) Erratum, Expert Opinion on Investigational Drugs, 21:8, 1241-1241, DOI: [10.1517/13543784.2012.709016](https://doi.org/10.1517/13543784.2012.709016)

To link to this article: <https://doi.org/10.1517/13543784.2012.709016>



Published online: 06 Jul 2012.



Submit your article to this journal [↗](#)



Article views: 272



View related articles [↗](#)

In the review article article entitled “Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia” by Anthony S Wierzbicki, Timothy C Hardman & Adie Viljoen, published in the May 2012 issue of Expert Opinion on Investigational Drugs (*Expert Opin Investig Drugs* (2012) 21(5): 667-676), an error has been identified that we would like to make our readers aware of.

As a result of an incorrect expansion of the term ‘PCSK9’ in the title, ‘pre-protein’ should have read ‘pro-protein’, and ‘serine’ should have read ‘subtilisin’. The complete title of the article should therefore read:

“Inhibition of pro-protein convertase subtilisin kexin 9 (PCSK9) as a treatment for hyperlipidaemia”.

The same error occurs on the first line of the abstract and also in the list of keywords.

In addition, part of the error (‘Pre-protein’ should read ‘Pro-protein’) also occurs in the heading for Section 2 and on the first line of text within this section.

Informa Healthcare apologise for this error and sincerely regret any inconvenience this may have caused our readers.

